Syndax Pharmaceuticals Inc [NASDAQ: SNDX] gained 21.10% or 2.19 points to close at $12.57 with a heavy trading volume of 9119194 shares.
It opened the trading session at $12.41, the shares rose to $12.98 and dropped to $11.9104, the range by which the price of stock traded the whole day. The daily chart for SNDX points out that the company has recorded -12.34% loss over the past six months.
If we look at the average trading volume of 2.26M shares, SNDX reached to a volume of 9119194 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Syndax Pharmaceuticals Inc [SNDX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SNDX shares is $34.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SNDX stock is a recommendation set at 1.23. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for Syndax Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 05, 2025. While these analysts kept the previous recommendation, Goldman raised their target price to Buy. The new note on the price target was released on July 10, 2025, representing the official price target for Syndax Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $37, while UBS analysts kept a Buy rating on SNDX stock.
The Price to Book ratio for the last quarter was 6.87, with the Price to Cash per share for the same quarter was set at 5.29.
Trading performance analysis for SNDX stock
Syndax Pharmaceuticals Inc [SNDX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 21.45. With this latest performance, SNDX shares gained by 43.99% in over the last four-week period, additionally sinking by -12.34% over the last 6 months – not to mention a drop of -4.92% in the past year of trading.
Syndax Pharmaceuticals Inc [SNDX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Syndax Pharmaceuticals Inc [SNDX] shares currently have an operating margin of -433.37% and a Gross Margin at 96.17%. Syndax Pharmaceuticals Inc’s Net Margin is presently recorded at -428.48%.
Syndax Pharmaceuticals Inc (SNDX) Capital Structure & Debt Analysis
According to recent financial data for Syndax Pharmaceuticals Inc. ( SNDX), the Return on Equity (ROE) stands at -113.22%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -62.43%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Syndax Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -69.33%, showcasing its effectiveness in deploying capital for earnings.
Syndax Pharmaceuticals Inc (SNDX) Efficiency & Liquidity Metrics
Based on Syndax Pharmaceuticals Inc’s (SNDX) latest financial statements, the Debt-to-Equity Ratio is 2.19%, indicating its reliance on debt financing relative to shareholder equity.
Syndax Pharmaceuticals Inc (SNDX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Syndax Pharmaceuticals Inc. (SNDX) effectively leverages its workforce, generating an average of -$1240703.7 per employee. The company’s liquidity position is robust, with a Current Ratio of 4.71% and a Quick Ratio of 4.55%, indicating strong ability to cover short-term liabilities.
Syndax Pharmaceuticals Inc [SNDX]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SNDX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Syndax Pharmaceuticals Inc go to 32.71%.
An analysis of Institutional ownership at Syndax Pharmaceuticals Inc [SNDX]
There are presently around $121.43%, or 123.02% of SNDX stock, in the hands of institutional investors. The top three institutional holders of SNDX stocks are: BLACKROCK INC. with ownership of 7.91 million shares, which is approximately 9.2721%. WELLINGTON MANAGEMENT GROUP LLP, holding 7.34 million shares of the stock with an approximate value of $$150.67 million in SNDX stocks shares; and WELLINGTON MANAGEMENT GROUP LLP, currently with $$117.47 million in SNDX stock with ownership which is approximately 6.7101%.
